A Pilot Study of Hemoporfin PDT in Children(2-7 Years Old) With Port-wine Stain

Inclusion Criteria: * Children with clinical diagnosis of PWS； * ≥2 years old and \<7 years old； * The guardians agreed to voluntarily participate in this study and signed the informed consent agreement Exclusion Criteria: * Therapy area located outside of head and neck; * Other skin diseases that might interfere with the efficacy evaluation; * Patients with respiratory disease, severe pulmonary dysfunction, history of airway hyperresponsiveness, or family history of suspected malignant hyperthermia; * Preexist scars in the treatment area caused by previous treatment, which might interfere with the efficacy and safety evaluation; * with allergic diseases; known to be allergic to eggs, milk or soy protein; known to have skin photoallergies, porphyria or known allergic history of experimental drugs (porphyrins) and chemically structure similar drugs; known allergic history of anesthetics; allergic constitution; * Cicatricial constitution; * Immunocompromised conditions or need long-term use of glucocorticoids and immunosuppressive agents; * Electrocardiographic abnormalities or organic heart diseases; * Hepatic or renal functions abnormal (alanine aminotransferase or aspartate transaminase or total bilirubin \> 1.5 upper limit of normal \[ULN\], or serum creatinine or blood urea nitrogen \> 1.5 ULN); * Coagulation disorders; * Patients with severe neurological, psychiatric, endocrine and cardiovascular diseases; with epilepsy history or recent epileptic seizures; * Be evaluated not suitable for anaesthesia by risk assessment before anaesthesia； * Previous therapy of PWS within the last 4 weeks; * Participation in any clinical studies within the last 4 weeks; * Be judged not suitable to participate the study by the investigators